Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEWAL: N-acetylcysteine in Advanced Atherosclerosis and Diabetes
NCT05908513Phase 1Withdrawn
- Sponsor
- University of Missouri
- Start
- Oct 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atherosclerosis, coronary artery disease (CAD) and peripheral artery disease (PAD) comparing NAC treatment with Placebo (2 arms). Primary endpoints: Change of blood pressure at 12 months, Change of biomarkers at 12 months and 2 more. Planned start Oct 2021; status: withdrawn.
02
Drugs
acetylcysteine
03
Conditions
atherosclerosiscoronary artery disease (CAD)peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT05908513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908513.